1 completed. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow CellabMED: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients YYB101 - Colorectal Cancer Metastatic, Colorectal Cancer Recurrent | Phase 1 / Phase 2 | Completed | CellabMED | 35 | 2019-08-09 | 2022-11-14 |
monoclonal antibody YYB-101 (1)
South Korea (1)
Garam Im (1) · Hoonkyo Kim, Ph.D (1)